Marching into the second decade after the approval of ipilimumab, it is clear that immune
checkpoint inhibitors (ICIs) have dramatically improved the prognosis of melanoma …

Glioblastoma is an aggressive primary brain tumor that has seen few advances in treatments
for over 20 years. In response to this desperate clinical need, multiple immunotherapy …

Preclinical studies show that locoregional CTLA-4 blockade is equally effective in inducing
tumor eradication as systemic delivery, without the added risk of immune-related side …

Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T
cell responses to model antigens, in various tumor settings. However, the impact of cross …

Background Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic
melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1 (sPD1) and PD-L1 (sPD …

Cancer vaccine is regarded as an effective immunotherapy approach mediated by dendritic
cells (DCs) which are crucial for antigen presentation and the initiation of adaptive immune …

Background: Mycosis fungoides (MF) and Sezary Syndrome (SS) are the most common
cutaneous T-cell lymphomas. It has been hypothesized that the interaction between the …

The innate immune system, composed of neutrophils, basophils, eosinophils, myeloid-
derived suppressor cells (MDSCs), macrophages, dendritic cells (DCs), mast cells (MCs) …

Glioblastoma (GBM) is a highly aggressive, infiltrative malignancy that cannot be completely
cured by current treatment modalities, and therefore requires more precise molecular …

Simple Summary The current standard of care for locally advanced melanoma is surgery first
followed by systemic therapy. However, there is growing evidence that neoadjuvant therapy …